Drug guidance
Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
Condition
Cancer
Urological
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex.